Your session is about to expire
← Back to Search
Exercise Training for Heart Disease (EXCEED Trial)
N/A
Waitlist Available
Led By Jennifer Reed, PhD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Patient is unwilling or unable to return for follow-up visits at 12 and 26 weeks
Patient is unable to provide written informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 12 weeks and baseline to 26 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether high-intensity interval training (HIIT) is better than moderate-intensity continuous exercise training (MICE) for improving exercise capacity and quality of life in women with coronary heart disease (CHD).
Who is the study for?
This trial is for English or French-speaking women with coronary heart disease who've had a related event or procedure at least 4 weeks ago but less than 12 weeks. They must be able to do an exercise test and have internet access. Women can't join if they have certain heart conditions, severe lung disease, are already exercising regularly, have unmanaged mental health issues, or can't commit to follow-up visits.
What is being tested?
The study compares high-intensity interval training (HIIT) with moderate-intensity continuous exercise (MICE) in improving exercise capacity and quality of life in women with coronary heart disease. Participants will be randomly assigned to one of the two exercise programs.
What are the potential side effects?
Exercise may cause temporary discomfort like muscle soreness or fatigue. High-intensity workouts could increase the risk of injury or cardiac events for those not accustomed to vigorous activity.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot commit to follow-up visits at 12 and 26 weeks.
Select...
I am unable to sign a consent form.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to 12 weeks and baseline to 26 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 12 weeks and baseline to 26 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Exercise capacity
Secondary study objectives
Anxiety
COVID-19 Signs and Symptoms, Complications and Treatments
Depression
+12 moreOther study objectives
Physical activity levels
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: standard care + moderate-intensity continuous exercise trainingExperimental Treatment1 Intervention
2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
Group II: standard care + high-intensity interval trainingExperimental Treatment1 Intervention
2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~820
Find a Location
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
194 Previous Clinical Trials
92,987 Total Patients Enrolled
Jennifer Reed, PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation
5 Previous Clinical Trials
282 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger